![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Active Filter(s):
Details:
The agreement grants development and commercialization rights for TDI01 to Graviton in all territories, excluding China.
Lead Product(s): TDI01
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: TDI01
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Graviton
Deal Size: $517.5 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 23, 2021